Testosterone Overprescription: Evidence-Based Criteria for Treatment

The Testosterone Prescription Problem

Testosterone replacement therapy (TRT) has become one of the fastest-growing prescriptions in men's medicine—not because testosterone deficiency is more prevalent, but because diagnostic criteria have been systematically lowered. Between 2000 and 2013, TRT prescriptions increased 500%, while the criteria for what constitutes "low testosterone" drifted downward. This creates a fundamental problem: we're treating men whose testosterone is low-normal as though they have pathological hypogonadism.

The issue isn't that testosterone therapy doesn't work. It does. The issue is who should receive it and when the risks exceed the benefits.

Understanding the Threshold Problem

The reference range for serum testosterone is typically 300–1000 ng/dL, established from population norms in healthy men. However, "normal" is not synonymous with "optimal for you," and critically, it's not synonymous with "deficient enough to treat."

A man with testosterone of 380 ng/dL is technically "in range," but may sit at the lower end of his genetic setpoint. Conversely, a man whose baseline testosterone is 220 ng/dL (below range) may represent a new equilibrium from metabolic dysfunction, not primary gonadal failure.

The American Urology Association (AUA) recommends TRT only when:

1. Serum testosterone <300 ng/dL on two separate morning measurements
2. Clinical hypogonadal symptoms (low libido, erectile dysfunction, fatigue, mood changes) are present
3. Secondary causes (obesity, sleep apnea, medication effects, liver disease) have been ruled out or optimized first

This is contraindicated in the current TRT-industrial complex, where a single test below 350 ng/dL often triggers prescriptions.

The Endocrine Cascade Problem

Testosterone doesn't function in isolation. It's the output of the hypothalamic-pituitary-gonadal (HPG) axis. When exogenous testosterone enters circulation, it suppresses LHRH (luteinizing hormone-releasing hormone) and subsequently LH and FSH. This feedback suppression is dose-dependent and reversible at moderate doses, but becomes permanent if the exogenous testosterone dose is high enough or used chronically without HCG co-administration.

Men prescribed TRT without HCG (human chorionic gonadotropin) will develop:

• Testicular atrophy (shrinkage of 20–30% volume within 3–6 months)
• Azoospermia (zero sperm count) if fertility is desired
• Dependence on exogenous testosterone indefinitely

This is a permanent reproductive cost that few men are counseled about before starting.

Red Flags: When TRT Backfires

TRT causes harm in specific populations:

1. Uncontrolled Sleep Apnea

Testosterone increases upper airway tone and can paradoxically worsen obstructive sleep apnea by increasing fluid retention and neck circumference. Men with untreated sleep apnea should optimize that first; testosterone therapy can then be added cautiously with repeat sleep studies.

2. Baseline Hematocrit >50% or Polycythemia

Testosterone stimulates erythropoiesis. Men with elevated baseline hematocrit (polycythemia) will develop dangerous blood viscosity on TRT. This requires phlebotomy or dose reduction.

3. Untreated Prostate Cancer

Testosterone is contraindicated. Prostate cancer is testosterone-dependent, and TRT accelerates progression.

4. Active Thrombotic Disease or Clotting Disorder

Testosterone increases hematocrit and fibrinogen, raising thrombotic risk in predisposed men.

5. Unoptimized Metabolic State

A man with 280 ng/dL testosterone, a BMI of 32, HbA1c of 6.2%, and poor sleep is a candidate for metabolic restoration, not TRT. Weight loss, sleep optimization, and glycemic control often restore testosterone to 450+ ng/dL naturally. TRT in this scenario masks the underlying dysfunction.

Pre-TRT Blood Testing Protocol

Before initiating testosterone therapy, order:

• Morning serum testosterone (8–10 AM, fasted; ≥2 measurements)
• Free testosterone (calculated or equilibrium dialysis if total is 300–450 ng/dL)
• LH and FSH (to distinguish primary vs secondary hypogonadism)
• Hematocrit and hemoglobin (baseline polycythemia screening)
• Prostate-specific antigen (PSA) (baseline; repeat annually on TRT)
• Lipid panel (testosterone can lower HDL and raise LDL in some men)
• Liver function tests (if using oral or topical agents; less relevant with injections)
• Estradiol (if baseline is >50 pg/mL, aromatization will be an issue on TRT)

The Synergistic Alternative: Peptides

For men with 250–400 ng/dL testosterone and mild symptoms, peptide therapy targeting the GH axis may be superior to direct TRT:

GHRH analogs (tesamorelin, CJC-1295) stimulate endogenous GH secretion. Elevated GH improves:

• Lean body mass
• Metabolic rate
• Sleep quality
• Collagen turnover

Improved sleep and reduced body fat often restore testosterone to 400–500 ng/dL endogenously, without HPG axis suppression. This preserves fertility and natural testosterone production while achieving the metabolic goals patients seek.

Bottom Line

Testosterone replacement is effective and appropriate for men with documented hypogonadism (testosterone <300 ng/dL) with concordant symptoms. It backfires when:

1. Prescribed to men in the low-normal range without symptoms
2. Used without HCG co-administration (destroying fertility)
3. Initiated in metabolically dysfunctional men who could restore testosterone naturally
4. Given to men with unscreened contraindications (sleep apnea, polycythemia, cancer risk)

The standard of care is screening first, optimizing second, treating third. Most men benefit far more from sleep optimization, weight loss, and peptide-based GH axis stimulation than from direct testosterone replacement.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.